Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug protocol tested for rare blood disorder

NCT ID NCT02203396

Summary

This study tested an optimized combination of three existing drugs (rabbit ATG, cyclosporine, and levamisole) as a first treatment for severe aplastic anemia. The treatment aimed to suppress the immune system's attack on the bone marrow and help blood counts recover. Researchers enrolled 40 newly diagnosed patients in China to see if this 9-day protocol was effective and safe.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, 300020, China

Conditions

Explore the condition pages connected to this study.